Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Novartis unit Sandoz Canada won Health Canada clearance for (Pr)Sandoz Semaglutide, a generic version of Novo Nordisk’s Ozempic. Label covers once-weekly treatment of type 2 diabetes in adults to improve glycemic control alongside lifestyle measures or other antidiabetic drugs. Authorization spans 0.25 mg, 0.5 mg, 1 mg
Health Canada granted marketing authorization for Sandoz Semaglutide, a generic version of Novo Nordisk’s Ozempic. Approval covers once-weekly subcutaneous use in adults with type 2 diabetes to improve glycemic control. Product set to launch in three dose strengths via two pen presentations. Sandoz sees no material 202